Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Brian H Kushner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Arnold J. Jacobs Pediatric Cancer Fund, Band of Parents Foundation, NCI NIH HHS.
Abstract (Originalsprache)
Myeloablative therapy (MAT) is included in high‐risk neuroblastoma (HR‐NB) treatment programs of the Children's Oncology Group (COG) and the Societe Internationale d'Oncologie Pediatrique Europe Neuroblastoma (SIOPEN), but not at Memorial Sloan Kettering Cancer Center (MSK). COG and SIOPEN programs achieved 3–5‐year event‐free survival rates of ~50%–60%, similar to the MSK experience without MAT which involved patients treated with COG or MSK induction and anti‐G D2 mAb murine‐3F8 + granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). We now present the first report on rapid COJEC without MAT. This retrospective study covers HR‐NB patients who received rapid COJEC but not MAT and had no prior progressive disease (PD) when referred to MSK during the era of availability of anti‐G D2 mAb naxitamab. The 28 subjects were diagnosed 1/2017–6/2023. Post‐COJEC, 10 had no distant disease (Group 1) and 18 had persistence of metastases (Group 2). Group 1 patients had resection of primary tumors and received 1–2 cycles of HR‐NB regimens (cyclophosphamide‐topotecan ± vincristine), local radiotherapy, and naxitamab + GM‐CSF; 9 also received anti‐NB vaccine. All 10 remain event‐free at median 3.5+ years post‐diagnosis. Group 2 patients received second‐line therapy post‐COJEC, including high‐dose cyclophosphamide + topotecan ± vincristine or cyclophosphamide + doxorubicin + vincristine. Treatment after all chemotherapy included naxitamab + GM‐CSF ± irinotecan‐temozolomide. Thirteen received vaccine. Twelve remain relapse‐free at median 2.4+ years post‐diagnosis, including 3 who developed secondary neoplasms—myelodysplastic syndrome ( n = 2, successfully treated) or thyroid carcinoma. Six developed PD (four are again in complete remission and two died of NB). Avoiding MAT after rapid COJEC does not appear to adversely affect outcome compared to rapid COJEC + MAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Brian H Kushner, Shakeel Modak
Förderung
- Arnold J. Jacobs Pediatric Cancer Fund
- Band of Parents Foundation
- NCI NIH HHS
- Katie's Find A Cure Fund
- Robert Steel Foundation
- Rhyan Loos Family Fund
- Robert K Steel Family Foundation
- National Cancer Institute
Zitieren
APA
Kushner, B. H., Basu, E. M., Cardenas, F. I., Kramer, K., & Modak, S. (2025). Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70043
Vancouver
Kushner BH, Basu EM, Cardenas FI, Kramer K, Modak S. Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma. International Journal of Cancer. 2025. doi:10.1002/ijc.70043
BibTeX
@article{Kushner2025,
author = {Kushner, Brian H and Basu, Ellen M and Cardenas, Fiorella Iglesias and Kramer, Kim and Modak, Shakeel},
title = {Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70043}
}
EUVIMED